In Q4-2011 US IOL procedure volume climbed a bit faster than recent trends have indicated, posting a 3.6 percent rise over procedure volume in Q4-2010.
While demand for toric IOLs has climbed sharply, outpacing that of other premium IOLs, the size of the astigmatic cataract patient population suggests a market opportunity barely tapped.
Regeneron’s Eylea entered the US market in late 2011 and has begun to reshape care for AMD patients and IVT injection regimens.
We expect the global retinal surgical device market to grow at a CAGR of more than 7 percent over the next five years, in part driven by newer implantable devices for severe vision loss.
Although the market is still in its infancy, we expect nearly a four-fold increase in the number of presbyopia-correcting surgeries by 2020.
This month's news includes the latest from Alimera Sciences, LensAR, Bausch + Lomb, NicOx, Thrombogenics and Avedro.
You are not currently logged in.
©2017 Market Scope
Lost your Password